Aha life's essential 8

Aha life's essential 8 has been studied in 1 paper since 2026: 1 observational study in people; 1 in the past year. The newest paper, Apr 17, 2026: “Cardiovascular Health at Midlife and Alzheimer Disease Biomarkers”.

Exposure

1 paper studies it2 findingsUpdated

See all 1 papers on aha life's essential 8

At a glance

The findings reach people, from one lab or study. 1 lab in 1 country.

“Compared to ideal LE8, intermediate (67.9% of participants) and poor (12.6%) LE8 was associated with lower Αβ42/40”
Cardiovascular Health at Midlife and Alzheimer Disease BiomarkersmedRxiv : the preprint server for health sciences2026doi:10.64898/2026.04.15.26350968

None of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 1 lab in 1 country
  • Funder: National Heart, Lung, and Blood Institute
  • Humans1

What did studies of aha life's essential 8 find?

2

Studies of aha life's essential 8 measured 2 outcomes: p-Tau217 and amyloid-beta 42/40 ratio.

p-Tau217

no changein humans1

1 study
  1. Aha life's essential 8 was not clearly linked with p-Tau217 in humans.

    Humansn = 1,406

More on p-Tau217

Amyloid-beta 42/40 ratio

downin humans1

1 study
  1. Aha life's essential 8 is linked with lower amyloid-beta 42/40 ratio in humans (intermediate or poor vs ideal LE8) (adjusted mean difference: -2.37, 95% CI: -2.38 to -2.36 and -2.38, 95% CI: -2.40 to -2.36, respectively).

    Humansintermediate or poor vs ideal LE8n = 1,406

More on Amyloid-beta 42/40 ratio

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 1May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 01 paper in 12 months